-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 23, 2021, Aadi Bioscience announced that the US FDA has approved the marketing of the innovative mTOR inhibitor Fyarro (ABI-009) for the treatment of locally advanced unresectable/metastatic malignant perivascular epithelioid cell tumors (PEComa) by intravenous injection.
This approval is based on positive data obtained from the drug in a phase 2 clinical trial
mTOR is a type of serine/threonine kinase.
Sirolimus, also known as rapamycin, is a commonly used specific mTOR inhibitor
PEComa is an ultra-rare subtype of soft tissue sarcoma driven by mTOR activation.
Reference materials:
[1] Aadi Bioscience Announces FDA Approval of its First Product Fyarro™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa).
(The original text has been deleted)